Gyre Therapeutics (GYRE) Misses Q1 EPS by 3c

Gyre Therapeutics (NASDAQ: GYRE) reported Q1 EPS of $0.00, $0.03 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $24.5 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Beyond Air, Inc. (XAIR) files for 5.42M share offering by selling stockholders
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c